Background: Preeclampsia is a disease specific from pregnancy. It is classified according to the age of symptoms onset as early (< 34 weeks) and late (≥34 weeks). Endocan is a biochemical marker of endothelial dysfunction that is potentially associated with immunoinflammatory response. It is known that endothelial dysfunction and inflammatory process are important features in preeclampsia (PE).

Aims: To evaluate endocan levels in preeclamptic women as a potential marker for prognosis and monitoring of PE.

Methods: This case-control study included 80 Brazilian pregnant women, 40 with severe PE and 40 normotensive pregnant women (Controls). From those 40 with severe PE, 20 had the early form and 20 the late form. Endocan levels were investigated by enzyme-linked immunosorbent assay. Statistical analysis was carried out using SPSS 19.0. Data normality was tested by Shapiro-Wilk test. The differences in endocan levels between the PE and normotensive groups were assessed by Mann-Whitney test. P values < 0.05 were considered statistically significant. Ethical aspects have been observed previously (CAAE 0530.0.203.00-09).

Results: No significant difference was observed between PE (0.388ng/mL [0.346-0.516]) versus normotensive pregnant (0.393ng/mL [0.321-0.623]) women (P=0.870). Additionally, no significant difference was found comparing early (0.385ng/mL [0.311-0.459]) versus late PE (0.407ng/mL [0.313-0.500]).

Conclusions: Our data showed no association between endocan levels and PE occurrence in Brazilian pregnant women, as well as the early and late form. These findings suggest that endocan seems not to be a potential marker for prognosis and monitoring of PE.
Support: CNPq (404353/2016-9) and FAPEMIG (00764-16)

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/assessment-of-endocan-as-a-marker-for-preeclampsia-and-its-clinical-forms/